Porphyria cutanea tarda in an HCV-positive liver transplant patient: a case report
Journal Title: Annals of Hepatology - Year 2012, Vol 11, Issue 6
Abstract
Introduction. Porphyria cutanea tarda (PCT) is the most common type of porphyria. The strong association between PCT and hepatitis C virus (HCV) infection is well established. Although antiviral treatment of chronic hepatitis C may improve PCT in some cases, de novo onset of PCT has been observed in patients under-going peginterferon/ribavirin treatment. We present a rare case of a genotype 3 HCV-positive liver transplant recipient who developed PCT during antiviral treatment and discuss its probable etiopathogenesis. Case presentation. A genotype 3 HCV-positive liver transplant recipient, a 42-year-old man, was treated with peginterferon alfa-2a (180 µg/week) combined with ribavirin (1,200 mg/day) for recurrence of HCV infection after liver transplantation. He presented with hyperferritinemia but tested negative for genetic hemochromatosis (C282Y and H63D mutations). During antiviral therapy, he developed skin lesions on his hands characterized by vesicles and erosions consistent with PCT. PCT was confirmed by skin biopsy and elevated urinary uroporphyrin levels (1,469 mg/24 h). He was treated with chloroquine (200 mg) twice weekly, resulting in gradual regression of the skin lesions. Antiviral treatment was stopped after 48 weeks, and the patient achieved a sustained virological response. In conclusion, we report an extremely rare case of PCT in a genotype 3 HCV-positive liver transplant patient treated with antiviral therapy. We believe that the combination of HCV genotype 3 infection; hemolysis due to ribavirin treatment; and increased plasma levels of cytokines, such as IL-6 and TNFα, could have altered the patient’s iron metabolism and thus caused PCT.
Authors and Affiliations
Adriano Pellicelli, Aldo Morrone, Luca Barbieri, Arnaldo Andreoli
Keywords
Related Articles
- EP ID EP78219
- DOI -
- Views 124
- Downloads 0
Treatment of chronic HBV infection in developing countries
Due to virological, host and socio-economic factors, the clinical presentation and treatment of chronic hepatitis B (CHB) differs between developing and developed countries and may differ between one low-income country...
Liver-specific case fatality due to chronic hepatitis C virus infection: a systematic review
Despite reports that mortality is increasing, overall case fatality due to hepatitis C virus (HCV) is thought to be low. Given the variability in published rates, we aimed to synthesize estimates of liver-specific case f...
Hormone replacement therapy in menopausal women: risk factor or protection to nonalcoholic fatty liver disease?
Percutaneous liver biopsy – 2 decades of experience in a public hospital in the South of Brazil
Introduction. Liver biopsy is a complementary method for diagnosis, staging and therapeutic guidance in liver diseases, where chronic viral hepatitis are the most acknowledged causes for the indication of histopathologic...
Predicting 6-week mortality after acute variceal bleeding: role of classification and regression tree analysis
Background. Available prognostic scores for mortality after acute variceal bleeding are mainly based on logistic regression analysis but may have some limitations that can restrict their clinical value. Aims. To assess t...